Compare Suven Life Sciences with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES TORRENT PHARMA SUVEN LIFE SCIENCES/
TORRENT PHARMA
 
P/E (TTM) x -79.4 35.1 - View Chart
P/BV x 1.2 8.9 14.0% View Chart
Dividend Yield % 1.8 0.7 268.9%  

Financials

 SUVEN LIFE SCIENCES   TORRENT PHARMA
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
TORRENT PHARMA
Mar-19
SUVEN LIFE SCIENCES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3381,964 17.2%   
Low Rs1691,245 13.6%   
Sales per share (Unadj.) Rs52.1453.4 11.5%  
Earnings per share (Unadj.) Rs6.825.8 26.5%  
Cash flow per share (Unadj.) Rs8.662.3 13.8%  
Dividends per share (Unadj.) Rs1.5017.00 8.8%  
Dividend yield (eoy) %0.61.1 55.8%  
Book value per share (Unadj.) Rs65.3279.2 23.4%  
Shares outstanding (eoy) m127.28169.22 75.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.5 137.5%   
Avg P/E ratio x37.162.2 59.6%  
P/CF ratio (eoy) x29.625.8 114.8%  
Price / Book Value ratio x3.95.7 67.6%  
Dividend payout %22.065.9 33.3%   
Avg Mkt Cap Rs m32,272271,513 11.9%   
No. of employees `0001.113.6 8.0%   
Total wages/salary Rs m66114,038 4.7%   
Avg. sales/employee Rs Th6,132.25,642.6 108.7%   
Avg. wages/employee Rs Th611.11,032.4 59.2%   
Avg. net profit/employee Rs Th803.5320.9 250.4%   
INCOME DATA
Net Sales Rs m6,63576,728 8.6%  
Other income Rs m242571 42.5%   
Total revenues Rs m6,87777,299 8.9%   
Gross profit Rs m1,60419,831 8.1%  
Depreciation Rs m2216,177 3.6%   
Interest Rs m385,038 0.7%   
Profit before tax Rs m1,5879,187 17.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m7181,254 57.3%   
Profit after tax Rs m8694,363 19.9%  
Gross profit margin %24.225.8 93.5%  
Effective tax rate %45.213.6 331.5%   
Net profit margin %13.15.7 230.4%  
BALANCE SHEET DATA
Current assets Rs m6,23250,375 12.4%   
Current liabilities Rs m1,49051,653 2.9%   
Net working cap to sales %71.5-1.7 -4,291.6%  
Current ratio x4.21.0 428.8%  
Inventory Days Days8692 93.9%  
Debtors Days Days8368 120.9%  
Net fixed assets Rs m4,04383,648 4.8%   
Share capital Rs m127846 15.0%   
"Free" reserves Rs m8,18346,397 17.6%   
Net worth Rs m8,31047,244 17.6%   
Long term debt Rs m1839,129 0.0%   
Total assets Rs m10,389141,209 7.4%  
Interest coverage x43.12.8 1,526.6%   
Debt to equity ratio x00.8 0.3%  
Sales to assets ratio x0.60.5 117.5%   
Return on assets %8.76.7 131.2%  
Return on equity %10.59.2 113.3%  
Return on capital %19.512.3 158.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62222,103 25.4%   
Fx outflow Rs m1,7995,522 32.6%   
Net fx Rs m3,82216,581 23.1%   
CASH FLOW
From Operations Rs m35617,981 2.0%  
From Investments Rs m-279-2,413 11.5%  
From Financial Activity Rs m-225-13,145 1.7%  
Net Cashflow Rs m-1482,380 -6.2%  

Share Holding

Indian Promoters % 63.4 71.5 88.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.0 -  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 8.8 414.8%  
Shareholders   37,287 26,511 140.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   UNICHEM LAB  ELDER PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  WOCKHARDT  

Compare SUVEN LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Mutual Fund Buying Activity in February, Easy Trip Planners IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended their day on a flat note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 35 points (up 0.1%).

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

Charge Your Portfolio with this Smallcap Proxy Play on India's EV Revolution(Profit Hunter)

Mar 5, 2021

This could be the biggest wealth creator of the decade.

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Mar 8, 2021 (Close)

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS